Latest stories on HRTX
Heron Therapeutics, Inc. (HRTX) CorMedix Inc., - M&A Call - Slideshow
Seeking Alpha58 · neutralm&a
Heron Therapeutics, Inc. (HRTX) M&A Call Transcript
Seeking Alpha50 · neutralm&a
Heron Therapeutics Agrees to Sell Assets to CorMedix
TipRanks58 · neutralm&a
HERON THERAPEUTICS, INC. /DE/ (HRTX) files 8-K
SEC 8-K50 · neutralgeneral
Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
Business Insider50 · neutralgeneral
Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
GlobeNewswire50 · neutralgeneral
Heron Therapeutics Expands U.S. Portfolio Through Licensing Deal
TipRanks56 · neutralproduct/pr
HERON THERAPEUTICS, INC. /DE/ (HRTX) files 8-K
SEC 8-K50 · neutralgeneral
Heron Therapeutics Earnings Call: Growth Meets New Risks
TipRanks56 · neutralearnings
Heron (HRTX) Q2 2026 Earnings Call Transcript
The Motley Fool34 · bearishearnings
Heron Therapeutics Extends Tax Benefit Preservation Plan Timeline
TipRanks50 · neutralgeneral
HERON THERAPEUTICS, INC. /DE/ (HRTX) files 8-K
SEC 8-K50 · neutralgeneral
Heron Therapeutics Downgraded To Neutral From Buy At H C Wainwright
The Fly50 · neutralanalyst
Heron Therapeutics Faces Nasdaq Delisting Risk as Share Price Falls Below $1 Threshold
TipRanks28 · bearishgeneral
Heron outlines covenants through 2027 and pro forma cash of $24.3M after September debt payment
Seeking Alpha28 · bearishgeneral
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook
Yahoo Top34 · bearishgeneral
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook
InvestorsHub34 · bearishgeneral
Heron Therapeutics Q2 Earnings Call Highlights
Yahoo Finance48 · neutralearnings
Heron Therapeutics GAAP EPS of -$0.03 misses by $0.02, revenue of $37.67M misses by $4.53M
Seeking Alpha28 · bearishearnings
HERON THERAPEUTICS, INC. /DE/ (HRTX) files 8-K
SEC 8-K50 · neutralgeneral
Heron Therapeutics Announces Second Quarter 2026 Financial Results
Business Insider63 · neutralearnings
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
Business Insider50 · neutralgeneral
Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?
Yahoo Finance56 · neutralanalyst
Heron Therapeutics Faces Nasdaq Minimum Bid Price Deficiency
TipRanks34 · bearishgeneral